Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses ...

Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its ...

If you look at a current version of the periodic table, it appears complete. Since 2010, the entire seventh period has been ...

ST. LOUIS, April 23, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials ...

Sakir Mutevelic, MD, Curium’s Chief Medical Officer said: “The successful start of patient enrollment is a significant step forward for Curium’s Phase 3 SOLAR-STAGE and SOLAR-RECUR clinical trials. As ...

ST. LOUIS, April 23, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials ...

About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe.

Try refreshing your browser, or tap here to see other videos from our team. Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol ...

But the conversation also covered the impact of AI on work which was considered from various perspectives. Carolyn Hicks said ...

The proposed acquisition of Eczacıbaşı-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium’s existing network in ...

The proposed acquisition of Eczacibasi-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium's existing network in ...